Premium
Zwitterionic polycarboxybetaine coating functionalized with REDV peptide to improve selectivity for endothelial cells
Author(s) -
Ji Ying,
Wei Yu,
Liu Xiangsheng,
Wang Jinlei,
Ren Kefeng,
Ji Jian
Publication year - 2012
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.34077
Subject(s) - umbilical vein , coating , surface modification , biofouling , materials science , methacrylate , endothelial stem cell , cell adhesion , adhesion , selectivity , peptide , protein adsorption , biophysics , chemical engineering , chemistry , nanotechnology , biochemistry , polymer , polymerization , in vitro , composite material , biology , catalysis , membrane , engineering
Surface immobilization of bioactive molecules has been a promising strategy to develop in situ endothelialization for cardiovascular implants. With the aim to construct endothelial cell specific coating with low fouling property, zwitterionic carboxybetaine methacrylate and butyl methacrylate were copolymerized as coating materials, spin‐coated onto substrates, and immobilized with endothelial cell selective peptide Arg‐Glu‐Asp‐Val (REDV) through functionalization of carboxy groups in carboxybetaine by NHS/EDC chemistry. Experimental results proved that carboxybetaine‐REDV coating maintained desirable antifouling ability and fine hemocompatibility. Separate culture and coculture of HUVECs (human umbilical vein endothelial cells) with HUASMCs (human umbilical artery smooth muscle cells) showed that the coating was able to enhance the competitive growth of endothelial cells while limiting the adhesion, proliferation, and migration of smooth muscle cells. The existence of zwitterionic carboxybetaine helps to screen undesirable adsorption of platelets, and its nonspecific resistance to smooth muscle cells contributes to the realization of endothelial cell selectivity. © 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 2012.